RECOMBINANT APOLIPOPROTEIN A-I MILANO DECREASES LEAFLET INFLAMMATION AND CALCIFICATION IN EXPERIMENTAL MODELS OF AORTIC STENOSIS  by Cimmino, Giovanni et al.
A152.E1426
JACC March 9, 2010
Volume 55, issue 10A
 VALVULAR HEART DISEASE
RECOMBINANT APOLIPOPROTEIN A-I MILANO DECREASES LEAFLET INFLAMMATION AND 
CALCIFICATION IN EXPERIMENTAL MODELS OF AORTIC STENOSIS
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Cellular Mechanisms in Valvular Disease
Abstract Category: Valvular Disease
Presentation Number: 1278-378
Authors: Giovanni Cimmino, Walter S. Speidl, Sammy Elmariah, Borja Ibanez, Randolph Hutter, Valentin Fuster, Juan Jose Badimon, Atherothrombosis 
Reserach Unit, Cardiovascular Institute, Mount Sinai Hospital, New York, NY
Background: Aortic stenosis (AVS) is associated with significant morbidity and mortality. ApoA-I Milano (ApoA-IM), a mutant form of ApoA-I, 
rapidly regresses established atherosclerotic lesions and associated inflammation. Recent data suggest that ApoA-IM may also reverse AVS in 
hypercholesteremic rabbit models. We aim to determine whether ApoA-IM treatment decreased leaflet inflammation and calcification associated 
with atherosclerosis in vivo, and to study in vitro the putative mechanism of action of the observed effects.
Methods: In vivo: AVS was induced in rabbits (n=20) by 9-months of 0.2% cholesterol diet. The presence of AVS was detected at the end of 
induction by ultrasound. Animals were then randomized to either ApoA-IM (two i.v. infusions 75 mg/kg 4-days apart) or placebo. Four days after the 
last dose, aortic valves were explanted and leaflets analyzed for RAM-11, MCP-1, and calcification by histopathology.
In vitro: Porcine aortic valve myofibroblasts (PAVMF) were cultured with oxidized-LDL (50 μg/ml) for 7 days. Effects of ApoA-IM pre-incubation on 
alkaline phosphatase (AP) expression and activity, a major player in the calcification process, were assessed.
Results: In vivo: ApoA-IM significantly reduced macrophages infiltration (RAM-11+) of valve leaflet tips vs. placebo (6.5±7.1% vs. 17.5±9.5%; 
p<0.05). Percentage of the total leaflet MCP-1 positive was also reduced in ApoA-IM-treated animals (6.1±4.1% vs. 11.3±6.3%; p<0.05). Calcium 
deposits were observed in 88% (7/8) of untreated rabbits and in only 25% (3/12) of ApoA-IM-treated rabbits (p<0.05).
In vitro: ox-LDL significantly increased AP activity in PAVMF vs control (15.4±1.5 vs 12.3±2.3ng/106 cells; p<0.001). Pre-incubation with ApoA-IM 
(140μg/mL) completely prevented ox-LDL-induced changes in AP activity (11.5±0.7 ng/106 cells; p<0.001). Similar effects were seen on AP gene 
expression.
Conclusions: ApoA-IM significantly reduces hypercholesterolemia-related aortic valve inflammation and calcification in vivo and decreases AP 
expression and activity in vitro. Our data suggest that HDL-raising intervention may be effective agents not only for atherosclerosis but also for AVS 
treatment.
